Synthesis and physiochemical characterizing of Liponiosomal hybrid nano-carriers as carriers for Doxorubicin HCl anti-cancer drug

Sasani, Elham; Shahi Malmir, Hashem; Daneshmand, Fatemeh; Majdizadeh, Mohammad; Haghiralsadat, Bibi Fatemeh

Document Type : Original Article

Authors

¹ MSc Department of Biology, Taft Payame Noor University, Yazd, Iran

² MSc Department of Biology, Nourdanesh Higher Education Institute, Meymeh, Isfahan, Iran

³ Assistant Professor, Biology Department of Payame Noor University, Tehran, Iran

⁴ MSc Nano-Biotech Foresight Company Biotechnology Campus, Science & Technology Park of Yazd, Yazd, Iran

⁵ PhD. Department of Advanced Medical Sciences and Technologies, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Abstract

Introduction: Lipid nano-carriers with slow release and semi-targeted delivery of the drug can reduce some of the challenges of drug delivery to cancer cells. The aim of this study was to prepare and evaluate physiochemicals of various formulations of the liponiosomal system containing doxorubicin in order to achieve targeted formulation in order to better fight cancer cells.
Methods: Nano-carriers were synthesized using different molar ratios of structural elements such as Dipalmitoylphosphatidylcholine, Cholesterol, Sorbitan ester and 3 out of 5 synthesized formulation were chose based on encapsulation efficiency. Then, in order to determine the final formula, release profiles comprised by dialysis and spectroscopy methods. The final formula was PEGylated by using DSPE-mPEG(2000) in order to investigate its effects on encapsulation efficiency and release profiles in healthy and cancerous cells simulated environment. Physiochemical characteristics such as size, zeta potential, Polydispersity Index(PDI), IR spectrum, and morphology were identified.
Results: The final PEGylated formula encapsulating doxorubicin had 102.9 nm size, 94.17±3.21% encapsulation efficiency, -6.67 mV zeta potential and 0.128 PDI. The maximum release rate of the drug for this nano-carrier in healthy and cancerous within 48 hours was 24.43% and 26.81% respectively. IR and morphological investigations showed no chemical interaction between drug and nanocarrier and the particles are spherical in shape.
Conclusion: The result of this research indicates that the PEGylated liponiosomal system, having the appropriate physiochemical properties, has not changed the chemical nature of drug and thus can be a suitable and semi-targeted carrier for doxorubicin.

Keywords

Main Subjects

Biotechnology & nanotechnology

References

[1]. Pecorino Lauren. Molecular biology of cancer mechanism, targets and therapeuticsy. 2th ed; 2008.

[2]. Cancer Control: a Global Snapshot in 2015 Summary of Results From the 2015 Who Ncd Country Capacity Survey. world Heal. Organ. 2015: 1-6

[3]. Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta (BBA)-General Subj. 2013; 1830(2): 2481-95.

[4]. Tinsley R. Harrison, Braunwald E. Harrison’s Principles of Internal Medicine. 17th ed. New York: The McGraw-Hill Companies, Inc; 2008.

[5]. Pigram W-J, Fuller W, Hamilton LD, Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature. 1972; 235(53): 17-19.

[6]. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 2000; 256(1): 42-9.

[7]. D. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J. Nucl. Cardiol. 2000; 7(1): 53-62.

[8]. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 2012; 30(7): 679-92.

[9]. Karewicz A, Bielska D, Loboda A, Gzyl-Malcher B, Bednar J, Jozkowicz A, Dulak J, Nowakowska M. Curcumin-containing liposomes stabilized by thin layers of chitosan derivatives. Colloids Surfaces B Biointerfaces. 2013; 109(1): 307-316.

[10]. Mirahmadi N, Babaei MH, Vali AM, Dadashzadeh S. Effect of liposome size on peritoneal retention and organ distribution after intraperitoneal injection in mice. Int. J. Pharm. 2010; 383(1): 7-13.

[11]. Daraee H, Etemadi A, Kouhi M, Alimirzalu S, Akbarzadeh A. Application of liposomes in medicine and drug delivery. Artif Cells, Nanomedicine, Biotechnol. 2016; 44(1): 381-91.

[12]. Cheraghi M, Negahdari B, Daraee H, Etemadi A. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. Biomed Pharmacother. 2017; 86(1): 316-23.

[13]. Mansoori MA, Agrawal S, Jawade S, Khan MI. A review on liposome. 2012; 2(4): 453-64.

[14]. Allen TM, Hansen CB, de Menezes DEL. Pharmacokinetics of long-circulating liposomes. Adv. Drug Deliv. Rev.1995; 16(2): 267-84.

[15]. Wang J, Ma W, Tu P. Synergistically Improved Anti‐tumor Efficacy by Co‐delivery Doxorubicin and Curcumin Polymeric Micelles. Macromol. Biosci. 2015; 15(9): 1252-61.

[16]. Majdizadeh M, Rezaei Zarchi S, Movahedpour AA, Shahi Malmir H, Sasani E, Haghiralsadat BF. A new strategy in improving therapeutic indexes of medicinal herbs: preparation and characterization of nano-liposomes containing Mentha piperita essential oil. J Shaeed Sdoughi Univ Med Sci Yazd. 2018; 25(10): 853-64.

[17]. Haghiralsadat BF, Amouabedini G, Naderinezhad S, Sheikhha MH, Malaei-balasi Z, Akbarzadeh A, et al. An evaluation of the transmembrane ammonium sulfate gradients method in lipid system to improve trapping capacity of amphipathic weak. New Cell Mol Biotechnol J. 2017; 7(28): 49-60

[18]. Rasoulian-broujeni M, Najafi S, Hojati-emami S, Dehghan mohammad mehdi. Preparation and evaluation of nanoparticles containing oxaliplatin for target drug release at the site of breast tumor. Iran J Breast Dis. 2011; 4(3): 33-43.

[19]. Shaikh IM, Tan KB, Chaudhury A, Liu Y, Tan BJB, Chiu GNC. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. J. Control. Release. 2013; 172(3): 852-61.

[20]. Alavi SE, Koohi-moftakhar-esfahani M, Akbarzadeh A. Evaluating the effect of nanoliposomal hydroxyurea urea on the breast cancer cell line. New Cellular & Molecular Biotechnology Journal. 2013; 3: 63-7.

[21]. Fang Y, Wu X, Chen J, Dang S, Jiang D, Chen M, et al. Preparation and Characterization of mPEG Modified Magnetic Long-Circulating Doxorubicin Hydrochloride Liposomes. Adv Mater Res. 2013; 661: 87-90.

[22]. Alavi SE, Koohi-moftakhari-esfahani M, Akbarzadeh A. Cytotoxic activity of pegylated nanoliposomal hydroxyurea in MCF-7 cell line. New Cellular & Molecular Biotechnology Journal. 2014; 4: 33-6.

[23]. Maedeh Koohi moftakhari esfahani, Alavi seyyed ebrahim, Akbaezadeh A. Drug delivery of pegylated nanoliposomal paclitaxel to breast. New Cell Mol Biotechnol J. 2014; 4(14): 47-50.

[24]. Alyane M, Barratt G, Lahouel M. Remote loading of doxorubicin into liposomes by transmembrane pH gradient to reduce toxicity toward H9c2 cells. SAUDI Pharm J. 2016; 24(2): 165-75.

[25]. Haghiralsadat BF, Amouabedini G, Sheikhha MH, Mohammadnezhad MJ, Nadernezhad S, Malaei-balasi Z, et al. New Approach for the Synthesis, Entrapment of Hydrophilic Drugs and Evaluation of Physico-Chemical Characteristics of PH-sensitive Nano-Liposome: Improving Therapeutic Efficacy of Doxorubicin in Order to Treatment Bone Tumor and Reducing the Side Effects. J Shaeed Sdoughi Univ Med Sci Yazd. 2016; 24(10): 780-9.

[26]. Haghiralsadat F, Amoabediny G, Sheikhha MH, Zandieh-doulabi B, Naderinezhad S, Helder MN, et al. New liposomal doxorubicin nanoformulation for osteosarcoma : Drug release kinetic study based on thermo and pH sensitivity. Chem Biol Drug Des. 2017; 90(3): 368-79.

[27]. Naderinezhad S, Haghiralsadat BF, Amouabedini G, Naderinezhad A, Esmaeili Z, Akbaezadeh A. Synthesis of biodegradable and self-assembled anionic nano-carrier: Novel approach for improvement of Curcumin- delivery to bone tumors cells & Mathematical modeling of drug-release kinetic. New Cell Mol Biotechnol J. 2017; 7(27): 77-84.

[28]. Shirzad M, Jamehbozorgi S, Aghabozorg H, Akbarzadeh A. Drug Delivery of Pegylated Nanoliposomal Cisplatin in Ovarian Cancer Cell Line A2780CP: in vitro Study. Vol. 7, New Cellular & Molecular Biotechnology Journal. 2017; 7: 77-84.

[29]. Naderinezhad S, Amouabedini G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Adv. 2017; 7(1): 30008-19.

[30]. Haghiralsadat BF, Nadernezhad S, Amoabediny G, Montazeri F, Zandieh-doulabi B. effects of surface charge on cytotoxicity of liposomal Doxorubicin on bone cancer cell line. Daneshvar Med. 2018; 25(133): 19-26.

[31]. Sasani E, Shahi Malmir H, Daneshmand F, Majdizadeh M, Haghiralsadat B F. A new study on synthesize and optimization of PEGylated LipoNiosomal nanocarriers containing curcumin for use in cancer chemotherapy . JSSU. 2018; 26 (6): 528-41

Journal of Sabzevar University of Medical Sciences

Synthesis and physiochemical characterizing of Liponiosomal hybrid nano-carriers as carriers for Doxorubicin HCl anti-cancer drug

References

References

Volume 27, Issue 1
May and June 2020
Pages 35-47

Synthesis and physiochemical characterizing of Liponiosomal hybrid nano-carriers as carriers for Doxorubicin HCl anti-cancer drug

References

References

Volume 27, Issue 1May and June 2020Pages 35-47

Volume 27, Issue 1
May and June 2020
Pages 35-47